From The Field: Clinical use of medical devices in the 'Bermuda Triangle'

Health Affairs

Volumn 23, Issue 1, 2004, Pages 200-207

  Kessler, Larry ^a   Ramsey, Scott D ^b   Tunis, Sean ^c   Sullivan, Sean D ^d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Centers Medicare and Medicaid Serv   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY CATHETER; BERMUDA; BIOAVAILABILITY; COMPUTER ASSISTED TOMOGRAPHY; DEVICE; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH SERVICE; LUNG CANCER; LUNG VOLUME; MEDICAID; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL SERVICE; MEDICAL TECHNOLOGY; MEDICARE; PULMONARY ARTERY; REDUCTION; REVIEW; SCREENING TEST; APPARATUS, EQUIPMENT AND SUPPLIES; ARTICLE; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; ORGANIZATION; UNITED STATES;

BIOMEDICAL TECHNOLOGY; DECISION MAKING, ORGANIZATIONAL; EQUIPMENT AND SUPPLIES; EVIDENCE-BASED MEDICINE; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES; UNITED STATES CENTERS FOR MEDICARE AND MEDICAID SERVICES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 4243132756     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.23.1.200     Document Type: Review

References (35)

1. S.A. Green, "The Evolution of Medical Technology: Lessons from the Burgess Shale," Clinical Orthopaedics (April 2001): 260-266; C. Myers and T. Green, "Medical Advancements Determine Health-System Capacity Requirements," Healthcare Financial Management 56, no. 3 (2002): 36-39; and S. Narayanan, "Technology and Laboratory Instrumentation in the Next Decade," Medical Laboratory Observer 32, no. 1 (2000): 24-27, 30-31.
2. S.A. Green, "The Evolution of Medical Technology: Lessons from the Burgess Shale," Clinical Orthopaedics (April 2001): 260-266; C. Myers and T. Green, "Medical Advancements Determine Health-System Capacity Requirements," Healthcare Financial Management 56, no. 3 (2002): 36-39; and S. Narayanan, "Technology and Laboratory Instrumentation in the Next Decade," Medical Laboratory Observer 32, no. 1 (2000): 24-27, 30-31.
3. S.A. Green, "The Evolution of Medical Technology: Lessons from the Burgess Shale," Clinical Orthopaedics (April 2001): 260-266; C. Myers and T. Green, "Medical Advancements Determine Health-System Capacity Requirements," Healthcare Financial Management 56, no. 3 (2002): 36-39; and S. Narayanan, "Technology and Laboratory Instrumentation in the Next Decade," Medical Laboratory Observer 32, no. 1 (2000): 24-27, 30-31.
4. B.G. Firth, "The Disconnect between the HCFA and the FDA," Journal of Invasive Cardiology 13, no. 2 (2001): 136-138, discussion 158-170; R.A. Merrill, "Regulation of Drugs and Devices: An Evolution," Health Affairs (Fall 1994): 47-69; R.A. Merrill, "Modernizing the FDA: An Incremental Revolution," Health Affairs (Mar/Apr 1999): 96-111; and J.A. DiMasi, "A New Look at United States Drug Development and Approval Times," American Journal of Therapeutics 3, no. 9 (1996): 647-657.
5. B.G. Firth, "The Disconnect between the HCFA and the FDA," Journal of Invasive Cardiology 13, no. 2 (2001): 136-138, discussion 158-170; R.A. Merrill, "Regulation of Drugs and Devices: An Evolution," Health Affairs (Fall 1994): 47-69; R.A. Merrill, "Modernizing the FDA: An Incremental Revolution," Health Affairs (Mar/Apr 1999): 96-111; and J.A. DiMasi, "A New Look at United States Drug Development and Approval Times," American Journal of Therapeutics 3, no. 9 (1996): 647-657.
6. B.G. Firth, "The Disconnect between the HCFA and the FDA," Journal of Invasive Cardiology 13, no. 2 (2001): 136-138, discussion 158-170; R.A. Merrill, "Regulation of Drugs and Devices: An Evolution," Health Affairs (Fall 1994): 47-69; R.A. Merrill, "Modernizing the FDA: An Incremental Revolution," Health Affairs (Mar/Apr 1999): 96-111; and J.A. DiMasi, "A New Look at United States Drug Development and Approval Times," American Journal of Therapeutics 3, no. 9 (1996): 647-657.
7. B.G. Firth, "The Disconnect between the HCFA and the FDA," Journal of Invasive Cardiology 13, no. 2 (2001): 136-138, discussion 158-170; R.A. Merrill, "Regulation of Drugs and Devices: An Evolution," Health Affairs (Fall 1994): 47-69; R.A. Merrill, "Modernizing the FDA: An Incremental Revolution," Health Affairs (Mar/Apr 1999): 96-111; and J.A. DiMasi, "A New Look at United States Drug Development and Approval Times," American Journal of Therapeutics 3, no. 9 (1996): 647-657.
8. Writing Group for the Women's Health Initiative, "Risks and Benefits of Estrogen plus Progestin in Healthy Post-Menopausal Women: Principal Results of the Women's Health Initiative Randomized Controlled Trial," Journal of the American Medical Association 288, no. 3 (2002): 321-333; and J.E. Rossouw et al., "The Evolution of the Women's Health Initiative: Perspectives from the NIH," Journal of the American Medical Women's Association 50, no. 2 (1995): 50-55.
9. Writing Group for the Women's Health Initiative, "Risks and Benefits of Estrogen plus Progestin in Healthy Post-Menopausal Women: Principal Results of the Women's Health Initiative Randomized Controlled Trial," Journal of the American Medical Association 288, no. 3 (2002): 321-333; and J.E. Rossouw et al., "The Evolution of the Women's Health Initiative: Perspectives from the NIH," Journal of the American Medical Women's Association 50, no. 2 (1995): 50-55.
10. Center for Devices and Radiological Health, An Introduction to Medical Device Regulation, Pub. no. FDA 92-4222 (Rockville, Md.: U.S. Food and Drug Administration, 1992).
11. Centers for Medicare and Medicaid Services, "Medicare Program: Criteria and Procedures for Extending Coverage to Certain Devices and Related Services," Federal Register (19 September 1995): 48417-48425; and 42 C.F.R., sec. 405. 201-215.
12. Centers for Medicare and Medicaid Services, "Medicare Program: Criteria and Procedures for Extending Coverage to Certain Devices and Related Services," Federal Register (19 September 1995): 48417-48425; and 42 C.F.R., sec. 405. 201-215.
13. CMS, "Procedures for Making Coverage Decisions," Federal Register (27 April 1999): 22619-22625.
14. M. Brenner et al., "New National Emphysema Treatment Trial Paradigm of Health Care Financing Administration-Sponsored Clinical Research Trials: Advances and Dilemmas," Journal of Investigative Medicine 50, no. 2 (2002): 95-100.
15. R.W. Taylor, J.E. Calvin, and G.M. Matuschak, "Pulmonary Artery Catheter Consensus Conference: The First Step," Critical Care Medicine 25, no. 12 (1997): 2064-2065.
16. A.F. Connors et al., "The Effectiveness of Right Heart Catheterization in the Initial Care of Critically Ill Patients," Journal of the American Medical Association 276, no. 11 (1996): 889-897; and J.E. Dalen and R.C. Bone, "Is It Time to Pull the Pulmonary Artery Catheter?" Journal of the American Medical Association 276, no. 11 (1996): 916-918.
17. A.F. Connors et al., "The Effectiveness of Right Heart Catheterization in the Initial Care of Critically Ill Patients," Journal of the American Medical Association 276, no. 11 (1996): 889-897; and J.E. Dalen and R.C. Bone, "Is It Time to Pull the Pulmonary Artery Catheter?" Journal of the American Medical Association 276, no. 11 (1996): 916-918.
18. S.D. Ramsey et al., "Clinical and Economic Effects of Pulmonary Artery Catheterization in Nonemergent Coronary Artery Bypass Graft Surgery," Journal of Cardiothoracic and Vascular Anesthesia 14, no. 2 (2000): 113-118;
19. J.S. Bender, M.A. Smith-Meek, and C.E. Jones, "Routine Pulmonary Artery Catheterization Does Not Reduce Morbidity and Mortality of Elective Vascular Surgery: Results of a Prospective, Randomized Trial," Annals of Surgery 226, no. 3 (1997): 229-236; and R.J. Valentine et al., "Effectiveness of Pulmonary Artery Catheters in Aortic Surgery: A Randomized Trial," Journal of Vascular Surgery 27, no. 2 (1998): 203-211.
20. J.S. Bender, M.A. Smith-Meek, and C.E. Jones, "Routine Pulmonary Artery Catheterization Does Not Reduce Morbidity and Mortality of Elective Vascular Surgery: Results of a Prospective, Randomized Trial," Annals of Surgery 226, no. 3 (1997): 229-236; and R.J. Valentine et al., "Effectiveness of Pulmonary Artery Catheters in Aortic Surgery: A Randomized Trial," Journal of Vascular Surgery 27, no. 2 (1998): 203-211.
21. J.D. Cooper and G.A. Patterson, "Lung-Volume Reduction Surgery for Severe Emphysema," Chest Surgery Clinics of North America 5, no. 4 (1995): 815-831.
22. U. Stammberger et al., "Buttressing the Staple Line in Lung Volume Reduction Surgery: A Randomized Three-Center Study," Annals of Thoracic Surgery 70, no. 6 (2000): 1820-1825.
23. J.D. Cooper, "Technique to Reduce Air Leaks after Resection of Emphysematous Lung," Annals of Thoracic Surgery 57, no. 4 (1994): 1038-1039.
24. H.F. Huizenga, S.D. Ramsey, and R.K. Albert, "Estimated Growth of Lung Volume Reduction Surgery among Medicare Enrollees: 1994 to 1996," Chest 114, no. 6 (1998): 1583-1587.
25. C.I. Henschke et al., "Early Lung Cancer Action Project: Initial Findings on Repeat Screening," Cancer 92, no. 1 (2001): 153-159.
26. J.E. Heffner and G. Silvestri, "CT Screening for Lung Cancer: Is Smaller Better?" American Journal of Respiratory and Critical Care Medicine 165, no. 4 (2002): 433-434.
27. J.B. Hall, "Use of the Pulmonary Artery Catheter in Critically 111 Patients: Was Invention the Mother of Necessity?" Journal of the American Medical Association 283, no. 19 (2000): 2577-2578; and G.R. Bernard et al., "Pulmonary Artery Catheterization and Clinical Outcomes: National Heart, Lung, and Blood Institute and Food and Drug Administration Workshop Report, Consensus Statement," Journal of the American Medical Association 283, no. 19 (2000): 2568-2572.
28. J.B. Hall, "Use of the Pulmonary Artery Catheter in Critically 111 Patients: Was Invention the Mother of Necessity?" Journal of the American Medical Association 283, no. 19 (2000): 2577-2578; and G.R. Bernard et al., "Pulmonary Artery Catheterization and Clinical Outcomes: National Heart, Lung, and Blood Institute and Food and Drug Administration Workshop Report, Consensus Statement," Journal of the American Medical Association 283, no. 19 (2000): 2568-2572.
29. Agency for Healthcare Research and Quality, Lung-Volume Reduction Surgery for End-Stage Chronic Obstructive Pulmonary Disease, Pub. no. 96-0062 (Rockville, Md.: AHRQ, 1996).
30. National Emphysema Treatment Trial Research Group, "Patients at High Risk of Death after Lung-Volume-Reduction Surgery," New England Journal of Medicine 345, no. 15 (2001): 1075-1083.
31. National Emphysema Treatment Trial Research Group, "A Randomized Trial Comparing Lung Volume Reduction Surgery with Medical Therapy for Patients with Severe Emphysema," New England Journal of Medicine 348, no. 21 (2003): 2059-2073; and National Emphysema Treatment Trial Research Group, "Cost Effectiveness of Lung-Volume-Reduction Surgery for Patients with Severe Emphysema," New England Journal of Medicine 348, no. 21 (2003): 2092-2102.
32. National Emphysema Treatment Trial Research Group, "A Randomized Trial Comparing Lung Volume Reduction Surgery with Medical Therapy for Patients with Severe Emphysema," New England Journal of Medicine 348, no. 21 (2003): 2059-2073; and National Emphysema Treatment Trial Research Group, "Cost Effectiveness of Lung-Volume-Reduction Surgery for Patients with Severe Emphysema," New England Journal of Medicine 348, no. 21 (2003): 2092-2102.
33. R.A. Smith and T.J. Glynn, "Current and Ongoing Challenges," Cancer Supplement 89, no. 11 (2000): 2327-2328.
34. National Emphysema Treatment Trial Research Group, "Patients at High Risk of Death"; and FDA, "Whole Body Scanning Using Computed Tomography," 17 April 2002, www.fda.gov/cdrh/ct (25 November 2002).
35. National Emphysema Treatment Trial Research Group, "Patients at High Risk of Death"; and FDA, "Whole Body Scanning Using Computed Tomography," 17 April 2002, www.fda.gov/cdrh/ct (25 November 2002).